Navigation Links
Saving Lives of California Residents Who Develop Skin Cancer Each Year: The Key is Early Detection and Treatment
Date:8/27/2007

San Diego Dermatologist Promoting Regular Skin Examinations

SAN DIEGO, Aug. 27 /PRNewswire/ -- Once every ninety minutes a California resident is diagnosed with a new case of melanoma skin cancer, according to the American Cancer Society. A local dermatologist is working to decrease this alarming statistic, and increase the likelihood that local residents diagnosed with this deadliest type of skin cancer will survive.

"Avoiding excessive exposure to direct sunlight and protecting your skin from harmful ultraviolet rays is the best defense against skin cancer, but it's equally important to have your skin examined at least once a year by a board-certified dermatologist, especially if you have any moles that are irregular in shape or have recently appeared or changed in size, shape or color," said Dr. Kenneth Gross of Skin Surgery Medical Group. "Early detection of suspicious pigmented lesions is the key to early diagnosis and the prevention of advanced melanoma."

When melanoma is caught in its early stages, it's almost always curable.

Risk factors for melanoma include:

* Sunburns

* Presence of many moles and/or large moles (>6mm)

* Fair skin, freckling, light eyes, or natural red or blond hair

* Family history of melanoma

* Past personal history of melanoma

Traditionally, dermatologists have relied on their own eyes and judgment in deciding whether to remove a suspicious mole.

Skin Surgery Medical Group is participating in a nationwide patient trial to test an investigational medical technology called MelaFind(R), designed to assist physicians in the early diagnosis of melanoma.

MelaFind is a non-invasive hand-held imaging device that emits light of multiple wavelengths to capture images of suspicious pigmented skin lesions (moles). MelaFind then analyzes the images in order to provide information to the physician and produce a recommendation of whether the lesion should be biopsied.

"We encourage patients to come in for skin exams in general, especially during the summer months when people tend to spend a lot of time outdoors in the sun," said Dr. Gross.

If you think you have a mole that may be cancerous, and would like to have it examined, please contact Skin Surgery Medical Group at 858-292-8641. You may also be eligible to participate in the MelaFind trial.

About Skin Surgery Medical Group, Inc.

At Skin Surgery Medical Group physicians and staff are dedicated to providing its patients with the best possible skin care. Dr. Gross at Skin Surgery Medical Group specializes in the following: skin cancer diagnosis and treatment including but not limited to melanoma, basal cell cancer, squamous cell cancer; diagnosis and treatment of moles and melanoma including sentinel node biopsy of lymph nodes; Mohs Surgery of skin cancer; evaluation and treatment of dysplastic nevus syndrome including use of episope evaluation of moles; skin flaps; skin grafts (full thickness and split thickness); cryosurgery for precancer and cancer; skin cancer surgery of lips, nails, ears, eyelids, and scalp; interferon for cancer, warts, and other skin problems. For more information visit http://www.skinsurgerymed.com.

Media Contact:

Erich Sandoval, Lazar Partners

Tel: (212) 867-1762

esandoval@lazarpartners.com


'/>"/>
SOURCE Skin Surgery Medical Group
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Prospective Model Outlined Potential Time and Cost Savings of Once-Monthly Anemia Treatment
2. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
3. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
4. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
5. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
6. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
7. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
8. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
9. CuraGen Presents Update on Clinical Development Program for Belinostat
10. Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos Bevirimat
11. New Critical Path Report Highlights Research Needed to Foster Generic Drug Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... 2, 2017  Eli Lilly and Company (NYSE: ... the third quarter of 2017 on Tuesday, October 24, ... that day with the investment community and media to ... conference call will begin at 9 a.m. Eastern time. ... live webcast of the conference call through a link ...
(Date:10/2/2017)... -- Halo Labs announces the European launch of their new low ... MIBio 2017 in Cambridge, U.K on October ... biopharmaceutical samples with unprecedented speed and sensitivity while using far less ... Imaging. ... analysis system ...
(Date:9/28/2017)... 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), will ... and webcast on Friday, November 3, 2017, beginning at ... at approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... financial performance and guidance for 2018, Hill-Rom executives will ... operational performance, and long-range financial outlook through 2020. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The International Association ... standards of excellence for the field of eating disorders, announces the opening of ... 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. , ...
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented ... the lowdown on sciatica in a new episode of "Success Files," which is ... events and innovation and investigates each subject in-depth with passion and integrity. , ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
(Date:10/12/2017)... ... 12, 2017 , ... Asante, a nationally recognized health system ... their existing home health joint venture through an agreement, effective October 1, 2017, ... venture home health company with Asante, delivering clinically integrated care, for the past ...
Breaking Medicine News(10 mins):